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background:  Fimasartan (Fms), is an angiotensin II antagonist with proven safety and efficacy for the treatment of essential hypertension 
in Korean population.
Methods:  Efficacy and safety of 60 and 120 mg once a day Fms, alone or with 12.5 mg hydrochlorothiazide (HCTZ) in adult Mexicans with 
grade 1-2 hypertension, was explored in an open, 6 month trial. Subjects took 60 mg Fms for 8 weeks; non-responders (Sitting Diastolic 
Blood Pressure [SiDBP ≥ 90 mmHg]) were then randomized to 120 mg Fms or 60 mg Fms + 12.5 mg HCTZ until week 12. At week 12, 
non-responders took Fms 120 mg + 12.5 mg HCTZ until study end. Responders (SiDBP <90mmHg) continued on their current treatment 
until study end.
Results:  272 subjects with age 54.9 ±9.7 years and baseline diastolic and systolic blood pressure of 94.22 ±4.37 and 150.85 ±10.63 
mmHg, were studied with the following Results: 
Week 8 Blood Pressure (BP) Changes from Baseline. Once Daily Fimasartan 60 mg (n=272)
Variable Week 8 change from Baseline (SD) p value* Response rate (%)
SiDBP (mmHg) -11.26 (8.92) p<0.0001 75.37
SiSBP (mmHg) -16.03 (14.09) p<0.0001
Week 12 BP Changes from Week 8. Once Daily Fimasartan 120 mg (n=29)
Variable Week 12 change from Week 8 Value (SD) p value* Response rate (%)
SiDBP (mmHg) -8.27 (8.14) p<0.0001 58.62
SiSBP (mmHg) -12.27 (12.5) p<0.0001
Week 12 BP Changes from Week 8. Once Daily Fimasartan 60 mg + HCTZ 12.5 mg (n=28)
Variable Week 12 change from Week 8 Value (SD) p value* Response rate (%)
SiDBP (mmHg) -10.78 (7.36) p<0.0001 78.57%
SiSBP (mmHg) -16.76 (13.22) p<0.0001
Week 24 BP Changes from Week 12. Once Daily Fimasartan 120 mg + HCTZ 12.5 mg (n=11)
Variable Week 24 change from Week 12 Value (SD) p value* Response rate (%)
SiDBP (mmHg) -13.90 (7.54) p=0.0001 72.73
SiSBP (mmHg) -19.54 (14.34) p=0.001
* paired t test
Between-randomized group comparisons were not statistically significant.
Sixteen (5.88%) subjects reported related adverse events (AE). None of 3 serious AE seen were fatal or Fms-related.
conclusion:  Once daily doses of Fms 60 mg, Fms 120 mg or Fms 60 mg + HCTZ 12.5 mg and Fms 120 mg + HCTZ 12.5 mg produced 
clinically relevant blood pressure decreases, with a safety profile consistent with that described in Korean Populations.
